<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916382</url>
  </required_header>
  <id_info>
    <org_study_id>SONIA 2</org_study_id>
    <nct_id>NCT01916382</nct_id>
  </id_info>
  <brief_title>Suitability of Nitisinone in Alkaptonuria 2</brief_title>
  <acronym>SONIA 2</acronym>
  <official_title>An International, Multicentre, Randomised, Evaluator-blind, No-treatment Controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Nitisinone in Patients With Alkaptonuria After 12 Months of Treatment, Followed by an Additional 36 Month Treatment Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proposal to develop the orphan designated drug, nitisinone, for the treatment of a&#xD;
      rare Mendelian disease, Alkaptonuria (AKU). Thanks to our existing successful fundamental and&#xD;
      clinical research (cell models, animal models, natural history studies), we are now ready for&#xD;
      this final stage of clinical development of nitisinone for AKU: a phase 3 clinical trial to&#xD;
      prove efficacy. The results of DevelopAKUre will allow us to make the case to the European&#xD;
      Medicines Agency for marketing authorisation of nitisinone for AKU, thereby contributing to&#xD;
      the goal of the International Rare Diseases Research Consortium of developing 200 new&#xD;
      therapies by 2020.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">February 2, 2020</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 houre Urine Homogentisic acid</measure>
    <time_frame>year 1</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Alkaptonuria</condition>
  <arm_group>
    <arm_group_label>Nitisinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Homogentisic acid lowering drug intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>comparrator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>drug</description>
    <arm_group_label>Nitisinone</arm_group_label>
    <other_name>Orfadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A patient must fulfil the following criteria in order to be included in the study:&#xD;
&#xD;
        1. Diagnosis of AKU Any Clinical manifestations of AKU, such as clinical ochronosis or&#xD;
        chronic back/joint pain.&#xD;
&#xD;
        3. Age â‰¥25 years. 4. Willing and able to visit the investigational site for study visits.&#xD;
        5. Signed written informed consent given.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a patient from inclusion in the study:&#xD;
&#xD;
          1. Currently pregnant or lactating.&#xD;
&#xD;
          2. Female patient of child-bearing potential not using a reliable method of&#xD;
             contraception.&#xD;
&#xD;
          3. Known allergy to nitisinone or any of the constituents of the investigational product.&#xD;
&#xD;
          4. Current malignancy.&#xD;
&#xD;
          5. Uncontrolled hypertension (blood pressure greater than 180 mmHg systolic or greater&#xD;
             than 95 mmHg diastolic).&#xD;
&#xD;
          6. Unstable cardiovascular disease.&#xD;
&#xD;
          7. Serum potassium &lt; 3.0 mmol/L.&#xD;
&#xD;
          8. eGFR &lt; 60 mL/min .&#xD;
&#xD;
          9. ALT &gt; 1.5 x upper limit of normal.&#xD;
&#xD;
         10. Haemoglobin &lt; 10.0 g/dL.&#xD;
&#xD;
         11. Platelets &lt; 100 x 109/L.&#xD;
&#xD;
         12. Total white blood count &lt; 3.0 x 109/L or neutrophil count &lt; 1.5 x 109/L.&#xD;
&#xD;
         13. History of alcohol or drug abuse.&#xD;
&#xD;
         14. Participation in another clinical study within 3 months of randomization.&#xD;
&#xD;
         15. Treatment with nitisinone within 60 days of randomization.&#xD;
&#xD;
         16. Psychiatric or somatic illness that interferes with compliance or communication with&#xD;
             health care personnel.&#xD;
&#xD;
         17. Foreseeable inability to cooperate with given instructions or study procedures.&#xD;
&#xD;
         18. Any other medical condition which in the opinion of the investigator makes the patient&#xD;
             unsuitable for inclusion.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L Ranganath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Professor Lakshminarayan Ranganath</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alkaptonuria, nitisinone,Ochronosis, Homogentisic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alkaptonuria</mesh_term>
    <mesh_term>Ochronosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 13, 2020</submitted>
    <returned>February 28, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

